Kai Brown

Kai Brown is an accomplished business development executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Vice President of Business Development at Abdera Therapeutics since August 2022, Brown has also been a Board Member for the National Hemophilia Foundation since December 2020. Previous roles include Corporate Development Consultant at AgileVentureRx, Senior Director at Bristol Myers Squibb's WW Commercial/Early Assets division, and Senior Director at MyoKardia, which was acquired by Bristol Myers Squibb. Brown's expertise encompasses market strategy, corporate development initiatives, and product launch execution, demonstrated through leadership positions at various organizations such as Portola Pharmaceuticals, Medivation, and BioMarin Pharmaceutical Inc. Educational credentials include an MBA from Stanford University Graduate School of Business, a Master's in Biotechnology from Columbia University, and a BA in Psychology and Biology from the University of Maryland Baltimore County.